Ainos (AIMD) Q2 2025 earnings summary

Executive summary

• Transitioned from R&D to commercial deployment of AI Nose, securing a $2.1M multi-year order and launching SmellTech-as-a-Service, with pilot deployments in industrial, robotics, and senior care sectors in Asia.

• Expanded strategic partnerships in robotics, semiconductors, and automation, with AI Nose achieving up to 90% accuracy in food/beverage scent classification and 85% in eldercare hygiene detection.

• Advanced VELDONA clinical trials in Taiwan for rare, autoimmune, and veterinary diseases, with promising interim results.

• Ceased COVID-19 test kit sales to focus on AI-powered scent digitization and VOC sensing products.

Financial highlights

• Q2 2025 revenue was $4,663, up from nil in Q2 2024; H1 2025 revenue reached $110,870, up 435% year-over-year, mainly from VOC sensing and AI Nose product sales.

• Q2 2025 net loss was $4,084,990, a 28% increase year-over-year; H1 2025 net loss was $7,371,012, up 13%.

• Gross margin improved to $3,726 in Q2 2025 from a $25,373 loss in Q2 2024; H1 2025 gross profit was $91,700 versus a $31,398 loss in H1 2024.

• Operating expenses rose 24% in Q2 2025 and 14% in H1 2025, mainly due to higher share-based compensation.

• Cash and cash equivalents were $1,223,184 as of June 30, 2025, down from $3,892,919 at year-end 2024.

Outlook and guidance

• 90-day roadmap targets completion of 1,400 AI Nose pilot deployments and expansion to 5,000 units, with potential scale-up to 15,000 units.

• Anticipates increased clinical trial spending for VOC POCT and VELDONA programs and higher R&D investment.

• Expects cash reserves, business revenues, and potential debt financing to fund operations for the next twelve months, but may need to raise additional capital.

• Management notes substantial doubt about ability to continue as a going concern without additional funding.

• Focus on expanding SmellTech-as-a-Service subscription model and pursuing strategic partnerships in Asia and Europe.